{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:05:19Z","timestamp":1777439119103,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12350-017-0799-x","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T15:15:30Z","timestamp":1486480530000},"page":"1559-1567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Rachelle","family":"Morgenstern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Castano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabahat","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-017-0799-x_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: The great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1007\/s12350-017-0799-x_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history 459 and therapy of TTR-cardiac amyloidosis: Emerging disease-460 modifying therapies from organ transplantation to stabilizer and 461 silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1007\/s12350-017-0799-x_bib3","doi-asserted-by":"crossref","first-page":"10_S","DOI":"10.1016\/S0735-1097(15)60971-8","article-title":"A phase 2, multi-center, open-label trail to evaluate the safety pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC, an RNAI therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"65","author":"Gillmore","year":"2015","journal-title":"JACC"},{"key":"10.1007\/s12350-017-0799-x_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-10-S1-O21","article-title":"Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"10","author":"Gillmore","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s12350-017-0799-x_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijcard.2015.05.155","article-title":"Novel potential therapeutic strategies of senile cardiac amyloidosis: Heat shock factor 1 blocks senile cardiac amyloidosis via HSPA1A in mouse model","volume":"195","author":"Qian","year":"2015","journal-title":"Int J Card Imaging"},{"issue":"4","key":"10.1007\/s12350-017-0799-x_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1007\/s12350-017-0799-x_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1007\/s12350-017-0799-x_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1007\/s12350-017-0799-x_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","article-title":"Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants","volume":"84","author":"Miller","year":"2004","journal-title":"Lab Investig"},{"key":"10.1007\/s12350-017-0799-x_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"10.1007\/s12350-017-0799-x_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12350-013-9803-2","article-title":"Nuclear imaging modalities for cardiac amyloidosis","volume":"21","author":"Bokhari","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib12","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12. doi:10.1161\/CIRCULATIONAHA.116.021612","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"10.1007\/s12350-017-0799-x_bib13","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.cardfail.2015.06.258","article-title":"Multicenter experience of technetium pyrophosphate scanning for diagnosing TTR cardiac amyloid: A revival in nuclear cardiology","volume":"21","author":"Castano","year":"2015","journal-title":"J Card Fail"},{"key":"10.1007\/s12350-017-0799-x_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib15","article-title":"Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","author":"Bokhari","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1023608115278","article-title":"Uptake of technetium 99m HDP in cardiac amyloidosis","volume":"19","author":"Kulhanek","year":"2003","journal-title":"Int J Card Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00003072-199903000-00002","article-title":"Tc-99m HDP uptake in cardiac amyloidosis","volume":"24","author":"Wadhwa","year":"1999","journal-title":"Clin Nucl Med"},{"key":"10.1007\/s12350-017-0799-x_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"10.1007\/s12350-017-0799-x_bib22","article-title":"Can 99m-Tc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis?","author":"Haq","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Casta\u00f1o","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib24","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: A pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","article-title":"A routine PET\/CT protocol with streamlined calculations for assessing cardiac amyloidosis using 18F-Florbetapir","volume":"2","author":"Osborne","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"10.1007\/s12350-017-0799-x_bib26","first-page":"e187","article-title":"Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: A pilot study","volume":"15","author":"Law","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-017-0799-x_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-017-0799-x_bib28","article-title":"Efficacy of volumetric quantification methods in 11C-PiB PET for diagnosing cardiac amyloidosis","volume":"56","author":"Park","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-017-0799-x_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib30","first-page":"S246","article-title":"Accurate semiautomatic analysis of cardiac 11 C-PIB retention in amyloidosis with Carimas software","volume":"41","author":"Kerol","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.111.045237","article-title":"Cardiac positron-emission tomography images with an amyloid-specific tracer in familial transthyretin-related systemic amyloidosis","volume":"125","author":"Furukawa","year":"2012","journal-title":"Circulation"},{"key":"10.1007\/s12350-017-0799-x_bib32","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1038\/ncomms8495","article-title":"Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography","volume":"6","author":"Irkle","year":"2015","journal-title":"Nat Commun"},{"key":"10.1007\/s12350-017-0799-x_bib33","first-page":"460","article-title":"Assessment of 18F-NaF PET\/CT as a diagnostic tool for early detection of coronary artery calcification","volume":"56","author":"Salavati","year":"2015","journal-title":"J Nucl Med."},{"key":"10.1007\/s12350-017-0799-x_bib34","first-page":"67","article-title":"Imaging ruptured coronary atherosclerotic plaques by use of CXCR4-targeted, motion corrected PET\/CT","volume":"57","author":"Derlin","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1007\/s12350-017-0799-x_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF00998166","article-title":"Soft-tissue uptake of 99m-Tc-diphosphonate and 99mTc-pyrophosphate in amyloidosis","volume":"16","author":"Janssen","year":"1990","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-017-0799-x_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12350-013-9800-5","article-title":"Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques","volume":"21","author":"AlJaroudi","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib37","first-page":"222","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"\u200eAm Heart J"},{"key":"10.1007\/s12350-017-0799-x_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","article-title":"Transthyretin cardiac amyloidoses in older North Americans","volume":"60","author":"Dharmarajan","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s12350-017-0799-x_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib40","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","article-title":"Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction","volume":"36","author":"Casta\u00f1o","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-017-0799-x_bib41","first-page":"284","article-title":"Binding of serum amyloid p-component (sap) by amyloid fibrils","volume":"38","author":"Pepys","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s12350-017-0799-x_bib42","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(88)92235-0","article-title":"Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid p component","volume":"1","author":"Hawkins","year":"1988","journal-title":"Lancet"},{"key":"10.1007\/s12350-017-0799-x_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1699-0463.1994.tb04893.x","article-title":"Calcium-enhanced aggregation of serum amyloid p component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study","volume":"102","author":"Nielsen","year":"1994","journal-title":"APMIS"},{"key":"10.1007\/s12350-017-0799-x_bib44","first-page":"163","article-title":"Cardiac involvement in systemic amyloidosis: Myocardial scintigraphic evaluation","volume":"15","author":"Hongo","year":"1985","journal-title":"J Cardiogr"},{"issue":"4","key":"10.1007\/s12350-017-0799-x_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s12350-015-0287-0","article-title":"[18F]-NaF PET\/CT imaging in cardiac amyloidosis","volume":"23","author":"Van Der Gucht","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-017-0799-x_bib46","article-title":"Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET\/CT?","author":"Gagliardi","year":"2016","journal-title":"J Nucl Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-017-0799-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-017-0799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812302384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812302384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-017-0799-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:03:32Z","timestamp":1761026612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107135812302384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S107135812302384X"],"URL":"https:\/\/doi.org\/10.1007\/s12350-017-0799-x","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-017-0799-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}